lergotrile mesylate

Lergotrile mesylate is a **synthetic nonpeptide ergot alkaloid derivative** and a **direct-acting dopamine receptor agonist**. It was developed primarily for the treatment of **Parkinson’s disease**, particularly for patients experiencing insufficient response or complications from levodopa therapy. The drug acts by stimulating dopamine receptors, leading to improvement in parkinsonian symptoms such as tremor, rigidity, bradykinesia, although its greatest benefit is seen in tremor reduction. Lergotrile mesylate also acts as a **prolactin secretion inhibitor**. However, its use was halted due to concerns over liver toxicity observed in clinical trials[1][3][4][8][10].

Other names

lergotrile mesylate2-chloro-6-methylergoline-8β-acetonitrile methanesulfonate